Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UPMC (University of Pittsburgh)

Sites in Pittsburgh, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1597
Shown on this page
12
Current sort
Recently updated
Campus scope
UPMC (University of Pittsburgh), Pittsburgh, PA
Additional filters apply within this campus.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this campus

These controls apply only within UPMC (University of Pittsburgh), Pittsburgh, PA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 553–564 of 1,597 matching trials with a site at UPMC (University of Pittsburgh), Pittsburgh, PA.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Recruiting Phase 2 Interventional

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

NCT06614322
Status at this site: Recruiting
View directory record Official record
Conditions
Chemotherapy Induced Peripheral Neuropathy (CIPN), Diabetic Peripheral Neuropathic Pain (DPN), Idiopathic Peripheral Neuropathy, Painful Peripheral Neuropathy
Interventions
Duloxetine, Placebo, Pregabalin
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 16, 2026, 10:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

NCT06427941
Status at this site: Recruiting
View directory record Official record
Conditions
Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer, Local Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Interventions
BGB-B2033, Bevacizumab, Tislelizumab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Goodyear, Arizona • Duarte, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 30, 2026, 8:21 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

NCT06226571
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemias
Interventions
Chemotherapy Regimen, HiDAC, Revumenib
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Goodyear, Arizona • Burbank, California • Duarte, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 13, 2026, 11:29 PM EDT
Recruiting Phase 2 Interventional

Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates

NCT06075745
Status at this site: Recruiting
View directory record Official record
Conditions
Liver Transplant
Interventions
CMV-MVA Triplex, Placebo for CMV-MVA Triplex
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • La Jolla, California • Redwood City, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 13, 2026, 7:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cerebrovascular Health and Resilience in Midlife

NCT06029348
Status at this site: Recruiting
View directory record Official record
Conditions
Cardiovascular Diseases, Cerebrovascular Disorders, Psychological Stress
Interventions
Paced Auditory Serial Addition Task
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years to 59 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 14, 2026, 11:35 AM EDT
Recruiting Not applicable Interventional

Acoustic Stimulation, Sleep, and Cognitive-Emotional Processes in Young Adults With Anxiety and Depression Symptoms

NCT05802004
Status at this site: Recruiting
View directory record Official record
Conditions
Acoustic Stimulation
Interventions
Acoustic Stimulation (STIM), Daily acoustic stimulation (STIM2), No Acoustic Stimulation (SHAM), No daily acoustic stimulation (SHAM2)
Device
Lead sponsor
Michelle Stepan
Other
Eligibility
18 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 14, 2026, 12:03 PM EDT
Active, not recruiting Not applicable Interventional

Cancer and Blood Pressure Management, CARISMA Study

NCT04467021
Site status not listed — check the official record
View directory record Official record
Conditions
Cardiovascular Disorder, Chronic Kidney Disease, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8
Interventions
Best Practice, Blood Pressure Measurement, Clinical Management, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
25
States / cities
Creve Coeur, Missouri • St Louis, Missouri • The Bronx, New York + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 13, 2026, 7:36 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

NCT04077099
Site status not listed — check the official record
View directory record Official record
Conditions
NSCLC
Interventions
REGN5093
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Orange, California • Washington D.C., District of Columbia • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 27, 2026, 2:16 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

NCT03831932
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Osimertinib, Positron Emission Tomography, Telaglenastat Hydrochloride, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Coral Gables, Florida • Deerfield Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 15, 2026, 1:32 AM EDT
Active, not recruiting Not applicable Interventional Results available

ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement

NCT03735667
Site status not listed — check the official record
View directory record Official record
Conditions
Aortic Stenosis
Interventions
ACURATE Prime™ Transfemoral TAVR System XL, ACURATE neo2™ Transfemoral TAVR System, Edwards SAPIEN 3 TAVR System, Medtronic CoreValve TAVR System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
1,948 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 10, 2026, 8:01 PM EDT
Recruiting Not applicable Interventional

tSCS in Children With Spina Bifida

NCT07615686
Status at this site: Recruiting
View directory record Official record
Conditions
Myelomeningocele, Spina Bifida
Interventions
Transcutaneous stimulator
Device
Lead sponsor
Bailey Petersen
Other
Eligibility
4 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 16, 2026, 12:57 AM EDT
Recruiting Phase 1 Interventional

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

NCT07493512
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
Xaluritamig
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
12
States / cities
Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 14, 2026, 4:10 PM EDT

About this UPMC (University of Pittsburgh) institution page

What this page lists
ClinicalTrials.gov records that list UPMC (University of Pittsburgh) in Pittsburgh, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.